Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare
View HTML
Toggle Summary AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022 Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan.
View HTML
Toggle Summary AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare
View HTML
Toggle Summary AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors
Robinson’s expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management team GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage
View HTML
Toggle Summary AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer
With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development  Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC’s preclinical
View HTML
Toggle Summary AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting
- Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) - GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting
View HTML
Toggle Summary AGTC Appoints Hope D’Oyley-Gay as General Counsel
Ms. D’Oyley-Gay brings significant legal experience as well as business development and commercial operations expertise from both biotech and pharmaceutical companies GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC),
View HTML
Toggle Summary AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021
-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET - GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation
View HTML
Toggle Summary AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases,
View HTML
Visionary science for life changing cures.